Chemistry:Vaniprevir

From HandWiki
Revision as of 05:00, 6 February 2024 by Unex (talk | contribs) (correction)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Vaniprevir
Vaniprevir.svg
Names
IUPAC name
(1R,21S,24S)-21-tert-Butyl-N-((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
EC Number
  • 682-506-7
KEGG
UNII
Properties
C38H55N5O9S
Molar mass 757.94 g·mol−1
Appearance White powder
Hazards
GHS pictograms GHS08: Health hazard
GHS Signal word Warning
H373
P260, P314, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Tracking categories (test):

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.[1] In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.[2][3]

References

  1. "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. March 2010. doi:10.1021/jm9015526. PMID 20163176. 
  2. "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014. http://www.datamonitorhealthcare.com/first-recommendation-for-hcv-drug-vaniprevir-in-japan/. 
  3. New Drugs Approved. Pharmaceuticals and Medical Devices Agency. http://www.pmda.go.jp/files/000197902.pdf.